Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Boston Examiner.
Press releases published on July 28, 2025
Eleos Deepens Post-Acute Care Mission with Home Health, Palliative, and Hospice Care Expansion
GlobeNewswire
·
July 28, 2025
CHICAGO and BOSTON, July 28, 2025 (GLOBE NEWSWIRE) -- Eleos Health, the market leader in AI for behavioral health, announced its expansion deeper into post-acute care, bringing its trusted, purpose-built AI platform to home health, palliative care and …
Acumen Pharmaceuticals Presents Studies Showing the Utility of a pTau217 Assay in Screening for a Phase 2 Alzheimer’s Disease Trial and Validates Sabirnetug Oligomer-Selectivity, at the Alzheimer’s Association International Conference (AAIC) 2025
GlobeNewswire
·
July 28, 2025
NEWTON, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s …
Chiesi Global Rare Diseases Spotlights the Profound Impact of Epidermolysis Bullosa in the Film “Living Between Pain and Hope” as part of “The Next Frontier,” a New Series Presented by the Biotechnology Innovation Organization
GlobeNewswire
·
July 28, 2025
BOSTON, July 28, 2025 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases (Chiesi) proudly shares its contribution to the thought-provoking film "Living Between Pain and Hope," as part of “The Next Frontier,” a series presented by the Biotechnology Innovation …
AMG and Montefiore Investment Announce Partnership
GlobeNewswire
·
July 28, 2025
AMG to invest in Montefiore, a leading European private equity firm with €5 billion in AUM, focused on the services sector Montefiore has a 20-year track record of consistently delivering top-tier returns by leveraging its differentiated strategy, sector …
CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod’s Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of…
GlobeNewswire
·
July 28, 2025
Based on the primary endpoint of Clinical Dementia Rating Sum of Boxes (CDR-SB), patients treated with neflamapimod showed 54% risk reduction in clinically significant worsening compared to control at Week 32 of treatment (p=0.0037). This risk reduction …